La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pharmarise Holdings Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Masayuki Akiyama

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	6.2yrs
Proprietà del CEO	0.4%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	6.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why Pharmarise Holdings (TSE:2796) Has A Meaningful Debt Burden

Aug 13

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 22

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Mar 07

AMMINISTRATORE DELEGATO

Masayuki Akiyama (62 yo)

6.2yrs

Mandato

Mr. Masayuki Akiyama is a President, COO & Representative Director of Pharmarise Holdings Corporation since August 2018 and serves as its Chief Executive Officer. He served as Senior Managing Director of P...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Masayuki Akiyama	President	no data	Nessun dato	0.36% ¥ 25.5m
Keiko Matsuura	Senior MD & Director	15.1yrs	Nessun dato	0.39% ¥ 27.5m
Toshimichi Ohno	Chairman of the Board	40.3yrs	Nessun dato	29.45% ¥ 2.1b
Sayoko Ohno	Vice Chairman of the Board	35.3yrs	Nessun dato	3.71% ¥ 260.9m
Makoto Miura	Auditor	less than a year	Nessun dato	0.075% ¥ 5.2m
Hiroshi Kanno	Director	4.2yrs	Nessun dato	0.082% ¥ 5.8m
Norio Watanabe	Independent External Director	9.2yrs	Nessun dato	0.024% ¥ 1.7m
Hiromu Tada	Independent External Director	8.2yrs	Nessun dato	Nessun dato
Yutaka Numata	Director	6.2yrs	Nessun dato	0.055% ¥ 3.9m
Ichijo Toda	Independent External Director	4.2yrs	Nessun dato	Nessun dato
Tsuneo Sonobe	Outside Audit & Supervisory Board Member	4.2yrs	Nessun dato	Nessun dato
Ai Aizawa	Director	less than a year	Nessun dato	Nessun dato

6.2yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2796 sono considerati esperti (durata media dell'incarico 6 anni).

Pharmarise Holdings Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pharmarise Holdings Corporation, Annual General Meeting, Aug 29, 2024

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Less than half of directors are independent

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: JP¥33.35 loss per share (vs JP¥35.42 profit in FY 2023)

Pharmarise Holdings Corporation to Report Q1, 2025 Results on Oct 10, 2024

Here's Why Pharmarise Holdings (TSE:2796) Has A Meaningful Debt Burden

Full year 2024 earnings released: JP¥33.35 loss per share (vs JP¥35.42 profit in FY 2023)

Pharmarise Holdings Corporation, Annual General Meeting, Aug 29, 2024

Upcoming dividend of JP¥20.00 per share

Pharmarise Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

New minor risk - Financial position

Third quarter 2024 earnings released: JP¥8.36 loss per share (vs JP¥14.43 profit in 3Q 2023)

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Pharmarise Holdings Corporation to Report Q3, 2024 Results on Mar 25, 2024

Pharmarise Holdings Corporation (TSE:2796) entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

Second quarter 2024 earnings released: EPS: JP¥15.10 (vs JP¥4.15 loss in 2Q 2023)

New minor risk - Shareholder dilution

Pharmarise Holdings Corporation to Report Q2, 2024 Results on Dec 25, 2023

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

First quarter 2024 earnings released: EPS: JP¥13.05 (vs JP¥11.87 in 1Q 2023)

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation to Report Q1, 2024 Results on Oct 11, 2023

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation Announces Commemorative Dividend for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Pharmarise Holdings Corporation to Report Fiscal Year 2023 Results on Jul 11, 2023

Upcoming dividend of JP¥14.00 per share at 2.2% yield

Third quarter 2023 earnings released: EPS: JP¥14.43 (vs JP¥7.70 in 3Q 2022)

Pharmarise Holdings Corporation (TSE:2796) entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2023

Second quarter 2023 earnings released: JP¥4.15 loss per share (vs JP¥20.05 profit in 2Q 2022)

Pharmarise Holdings Corporation to Report Q2, 2023 Results on Dec 29, 2022

Less than half of directors are independent

First quarter 2023 earnings released: EPS: JP¥11.87 (vs JP¥6.78 in 1Q 2022)

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2023

Pharmarise Holdings Corporation to Report Q1, 2023 Results on Oct 13, 2022

Pharmarise Holdings Corporation Announces Cash Dividend for the Year Ended May 31, 2022, Payable on August 26, 2022; Provides Dividend Guidance for the Year Ending May 31, 2023

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Full year 2022 earnings released: EPS: JP¥47.90 (vs JP¥45.78 in FY 2021)

Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Two Dispensing Pharmacies.

Pharmarise Holdings Corporation to Report Fiscal Year 2022 Results on Jul 08, 2022

Upcoming dividend of JP¥14.00 per share

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: JP¥7.70 (vs JP¥1.40 loss in 3Q 2021)

Pharmarise Holdings Corporation to Report Q3, 2022 Results on Apr 12, 2022

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: EPS JP¥6.78 (vs JP¥5.93 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥45.78 (vs JP¥61.03 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Third quarter 2021 earnings released: JP¥1.40 loss per share (vs JP¥11.69 profit in 3Q 2020)

Pharmarise Holdings Corporation to Report Q3, 2021 Results on Apr 14, 2021

Second quarter 2021 earnings released: EPS JP¥19.54

Pharmarise Holdings Corporation to Report Q2, 2021 Results on Jan 14, 2021

Pharmarise Holdings Corporation to Report Q1, 2021 Results on Oct 15, 2020

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media